BioLife Solutions (NASDAQ:BLFS) EVP Aby Mathew Sells 529 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby Mathew sold 529 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $20.74, for a total value of $10,971.46. Following the completion of the transaction, the executive vice president directly owned 392,937 shares in the company, valued at approximately $8,149,513.38. This represents a 0.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

BioLife Solutions Trading Down 3.3%

NASDAQ BLFS traded down $0.66 during trading hours on Friday, hitting $19.46. 191,494 shares of the company’s stock traded hands, compared to its average volume of 403,642. BioLife Solutions, Inc. has a 52 week low of $19.10 and a 52 week high of $29.62. The firm has a market capitalization of $939.92 million, a P/E ratio of -176.89 and a beta of 1.90. The business’s fifty day moving average price is $23.47 and its two-hundred day moving average price is $25.10.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. grew its holdings in BioLife Solutions by 27.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider’s stock valued at $125,273,000 after buying an additional 1,113,972 shares in the last quarter. Invesco Ltd. grew its stake in shares of BioLife Solutions by 9.2% during the fourth quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider’s stock valued at $95,080,000 after buying an additional 332,747 shares during the last quarter. XTX Topco Ltd raised its holdings in shares of BioLife Solutions by 280.4% in the fourth quarter. XTX Topco Ltd now owns 36,262 shares of the medical equipment provider’s stock worth $877,000 after buying an additional 26,729 shares during the period. SummitTX Capital L.P. purchased a new position in BioLife Solutions during the 4th quarter valued at $1,747,000. Finally, Sandler Capital Management bought a new position in BioLife Solutions in the 4th quarter valued at $765,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on BLFS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $32.00 price target on shares of BioLife Solutions in a research report on Monday, December 29th. Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. UBS Group restated a “buy” rating on shares of BioLife Solutions in a research note on Monday, December 29th. Finally, Northland Securities set a $34.00 target price on BioLife Solutions in a research note on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, BioLife Solutions currently has an average rating of “Moderate Buy” and an average price target of $32.00.

Key BioLife Solutions News

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Analyst/preview piece says BioLife completed a strategic refocus on core biopreservation media and vials, expects ~17–20% revenue growth in FY2026, positive GAAP net income and mid‑60s gross margins; cites PanTHERA acquisition and QKine partnership as drivers of higher ARPU and product launches late‑2026. BioLife Looks Strong For Fiscal Year 2026
• Positive Sentiment: Company presentation/press release reiterated growth and strategic refocus, supporting management’s turnaround narrative and guidance to investors. BioLife Solutions Highlights Growth and Strategic Refocus in Presentation
• Neutral Sentiment: Reported short‑interest metrics show zero shares / 0.0 days‑to‑cover — figures appear erroneous or non‑informative, so there’s no clear evidence of significant short pressure at present. MarketBeat BLFS
• Negative Sentiment: Several senior insiders (CFO, CMO, EVP, CTO and others) disclosed open‑market sales of modest blocks (hundreds of shares each at ≈$20.74). While amounts are small relative to their holdings, clustered executive selling can create near‑term investor concern and headline risk. Insider trading alert

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.